Core Viewpoint - Standard Chartered Bank Hong Kong, Animoca Brands, and HKT are forming a joint venture to issue a stablecoin backed by the Hong Kong dollar, pending the enactment of the Stablecoins Bill and obtaining a license from the Hong Kong Monetary Authority (HKMA) [1][2]. Group 1: Joint Venture Details - The joint venture aims to leverage Standard Chartered's banking infrastructure, Animoca Brands' Web3 expertise, and HKT's mobile wallet capabilities to create a stablecoin [2][3]. - The stablecoin is intended to enhance domestic and cross-border payments for both consumers and merchants [3]. Group 2: Regulatory Context - The HKMA's stablecoin bill is currently under review, which will require issuers to obtain a license and adhere to reserve and price stability requirements [2]. - The joint venture has been participating in an HKMA stablecoin issuer sandbox since July to explore the role of stablecoins in financial markets and payments [3]. Group 3: Strategic Goals - The CEO of Standard Chartered emphasized the goal of launching a secure stablecoin for various use cases, reinforcing Hong Kong's position as an international finance center [4]. - Standard Chartered is also involved in a separate pilot project, the Canton Network, which investigates a privacy-enabled open blockchain network for real-time settlement [4]. Group 4: Related Initiatives - The HKMA has initiated the second phase of testing for its e-HKD Pilot, involving 11 groups exploring tokenized assets and offline payments [5].

Core Viewpoint - The article discusses a class action lawsuit against Joint Stock Company Kaspi.kz, alleging violations of the Securities Exchange Act of 1934 due to misleading statements and undisclosed risks related to its business operations with Russian entities following the 2022 invasion of Ukraine [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Krivenok v. Joint Stock Company Kaspi.kz and covers purchasers of Kaspi.kz securities from January 19, 2024, to September 19, 2024 [1]. - Investors have until February 18, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Kaspi.kz continued business with Russian entities and provided services to Russian citizens, exposing the company to undisclosed sanction risks [3]. Group 2: Allegations and Impact - The lawsuit claims that Kaspi.kz engaged in undisclosed related party transactions and that certain executives have links to reputed criminals [3]. - A report by Culper Research on September 19, 2024, titled "Kaspi.kz (KSPI): The NASDAQ-Listed Fintech Moving Money for Criminals and Kleptocrats," led to a nearly 19% drop in the price of Kaspi.kz American depositary shares over two trading sessions [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Kaspi.kz securities during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm of their choice for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having recovered $6.6 billion for investors in such cases [6]. - The firm has been ranked 1 in securing monetary relief for investors in six out of the last ten years [6].

SAN DIEGO, Feb. 15, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) publicly traded securities between January 19, 2024 and September 19, 2024, inclusive (the “Class Period”), have until this Tuesday, February 18, 2025 to seek appointment as lead plaintiff of the Kaspi.kz class action lawsuit. Captioned Krivenok v. Joint Stock Company Kaspi.kz, No. 24-cv-10926 (C.D. Cal.), the Kaspi.kz class action lawsuit charge ...

MIAMI, Feb. 14, 2025 /PRNewswire/ -- Safe and Green Development Corporation (NASDAQ: SGD) (the "Company") is pleased to announce that all 5 homes from the 1stt phase of the Sugar Joint Venture with Milk & Honey, LLC have all gone under contract. These transactions mark a significant milestone in the Company's ongoing real estate initiatives and reflect the demand for high-quality housing in the region.As a result of successful marketing efforts by the Company and its Realty partners the following properties ...

-Jumps 29 Spots on Franchise 500 Ranking-SCOTTSDALE, Ariz., Feb. 13, 2025 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, has been named the top franchise in chiropractic services by Entrepreneur Magazine's Franchise 500, the world's first and most comprehensive franchise ranking. The Joint also ranks No. 54 on the 2025 list, jumping 29 spots since last year. For 46 years, achieving placement on the annual Entreprene ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Joint Stock Company Kaspi.kz regarding a class action lawsuit due to allegations of misleading statements and undisclosed risks associated with the company's operations during a specific period [1][2]. Allegations - The complaint alleges that Kaspi.kz continued business with Russian entities and provided services to Russian citizens after Russia's invasion of Ukraine, exposing the company to undisclosed sanction risks [1]. - The company is accused of engaging in undisclosed related party transactions [1]. - Certain executives of Kaspi.kz reportedly have links to reputed criminals [1]. - As a result, statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from January 19, 2024, to September 19, 2024 [1]. - Shareholders are encouraged to register for the class action by February 18, 2025, to potentially become lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies adhere to responsible business practices and good corporate citizenship [3].

The Company's revolutionary system enhances steel pressure pipe resilience in differential settlement and seismic applicationsVANCOUVER, Wash., Feb. 12, 2025 /PRNewswire/ -- Northwest Pipe Company (Nasdaq: NWPX), a leading manufacturer of water-related infrastructure, is proud to announce that the United States Patent and Trademark Office has issued U.S. Patent No. 12215817 for the InfraShield® Joint System ("InfraShield®"), an innovative Geohazard Resistant Steel Pipe (GRSP) solution designed to strengthen ...

Group 1: Partnership Overview - TriNetX has partnered with Fujitsu to form TriNetX Japan K.K., aiming to utilize anonymized electronic health record (EHR) data from Japanese patients to enhance clinical trials and drug development [1][4] - The joint venture represents a significant advancement in integrating Japan into the global data-driven medicine landscape, leveraging Japan's status as the third-largest pharmaceutical market [2][3] Group 2: Strategic Goals and Benefits - The collaboration aims to create an environment for efficient use of previously underutilized Japanese medical data for clinical research, ultimately improving patient treatment options [5] - The new entity will integrate TriNetX's global network of over 200 million patient records with Fujitsu's cloud-based healthcare platform, facilitating access to large-scale EHR datasets for researchers and pharmaceutical companies [4][5] Group 3: Leadership and Future Directions - Shogo Wakabayashi has been appointed as the Country Manager for TriNetX Japan K.K., with key executives from TriNetX serving on the Board of Directors [6] - The initiative aligns with the increasing participation of Japanese medical institutions in the TriNetX network, fostering novel studies and clinical trial opportunities [5]

Core Viewpoint - Oramed Pharmaceuticals Inc. has announced the spin-off of its Protein Oral Delivery (POD™) technology into a new joint venture, OraTech Pharmaceuticals Inc., aimed at accelerating the development and commercialization of oral insulin and other innovative oral drug delivery technologies [1][2][4]. Group 1: Company Structure and Financials - Oramed will transfer its proprietary oral insulin and POD™ technology, along with other pipeline assets, into OraTech, allowing Oramed shareholders to receive a majority equity interest in the new entity [2][7]. - Oramed and Hefei Tianhui Biotech Co., Ltd. (HTIT) will contribute a combined $75 million in capital to OraTech, with HTIT investing $60 million and Oramed investing $15 million [2][7]. - OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology [7]. Group 2: Strategic Focus and Development Plans - OraTech will focus on bringing oral insulin to market and exploring broader applications of oral drug delivery for additional therapeutic targets [3][4]. - A pivotal Phase 3 clinical trial in the United States is planned to be reinitiated, with a revised protocol expected to begin this quarter [7]. - OraTech aims to advance the registration of oral insulin in the U.S. and other countries, and will receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted [7]. Group 3: Manufacturing and Operational Capabilities - OraTech will leverage HTIT's advanced manufacturing capabilities, particularly in capsule production, to ensure a robust and scalable supply chain for clinical trials and commercialization efforts [3][4]. - The collaboration is expected to enhance the development and commercialization of Oramed's ORMD-0801 oral insulin and other POD™-based technologies, reinforcing the vision of revolutionizing diabetes and chronic disease treatments [1][8].

Core Points - Golden Arrow Resources Corporation has amended its option agreement with Mogotes Metals Inc. for the Mogote Copper-Gold Project in Argentina, allowing Mogotes Metals to acquire a 100% interest in the project for CAD$1 million, which includes cash, a private placement, and a 1.5% net smelter returns royalty [1][2][3] Financial Details - Mogotes Metals will pay CAD$550,000 in cash and invest CAD$450,000 through a private placement at a minimum price of CAD$0.05 per unit, with each unit consisting of one common share and one warrant [3][4] - The agreement includes the issuance of 10,714,285 common shares of Mogotes Metals to Golden Arrow on the initial closing date, with additional shares valued at CAD$1.5 million to be issued within one year [4][5] Project Development - Golden Arrow is advancing exploration at its Caballos Copper-Gold Project, where drilling has commenced, marking the first drill testing of the property [2][7] - The initial drilling program at Caballos is expected to include three holes totaling approximately 1,000 meters [2] Strategic Outlook - The company aims to utilize the cash from the amended agreement to further explore its active projects in Argentina and Chile, particularly the San Pietro copper-gold-iron-cobalt project [2][7] - The strategy of optioning non-core assets is beginning to yield positive results, with expectations for a productive year ahead [2][7]